Changes in T-helper cell function in human immunodeficiency virus-infected children during didanosine therapy as a measure of antiretroviral activity

Mario Clerici, Emmanuel Roilides, Karina M. Butler, Louis DePalma, David Venzon, Gene M. Shearer, Philip A. Pizzo

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Didanosine has shown activity against the human immunodeficiency virus (HIV) in both children and adults. We prospectively assessed T-helper cell (Th) function as determined by in vitro interleukin-2 (IL-2) production in response to a panel of T-cell stimuli in 22 HIV-infected children before and during didanosine therapy and we correlated the incidence of opportunistic and recurrent bacterial infections with changes in p24 antigen and CD4 counts. Didanosine (270, 360, or 540 mg/m2/d) was administered orally for periods ranging from 8 to 40 weeks (mean, 24 weeks). Five of six asymptomatic patients (Centers for Disease Control P-1) compared with 6 of 16 symptomatic (P-2) patients exhibited improved Th function (greater than threefold increase in IL-2 production to at least 2 of the 4 stimuli) during therapy. Of 12 patients without infections during therapy, 9 (75%) showed improvement in Th function, compared with only 2 of 10 patients with infections (P = .03). Notably, the incidence of infections was not correlated with improvements in CD4 count or decreases in p24 antigen. Improvement in Th function during didanosine therapy is correlated with decreased incidence of infections. Assessment of Th function may provide an additional measurement of immunologic response to antiretroviral therapy. This is a US government work. There are no restrictions on its use.

Original languageEnglish
Pages (from-to)2196-2202
Number of pages7
JournalBlood
Volume80
Issue number9
Publication statusPublished - Nov 1 1992

Fingerprint

Didanosine
Helper-Inducer T-Lymphocytes
Viruses
HIV
CD4 Lymphocyte Count
Infection
Interleukin-2
Incidence
Disease control
Therapeutics
Antigens
CD4 Antigens
T-cells
Centers for Disease Control and Prevention (U.S.)
Bacterial Infections
T-Lymphocytes

ASJC Scopus subject areas

  • Hematology

Cite this

Clerici, M., Roilides, E., Butler, K. M., DePalma, L., Venzon, D., Shearer, G. M., & Pizzo, P. A. (1992). Changes in T-helper cell function in human immunodeficiency virus-infected children during didanosine therapy as a measure of antiretroviral activity. Blood, 80(9), 2196-2202.

Changes in T-helper cell function in human immunodeficiency virus-infected children during didanosine therapy as a measure of antiretroviral activity. / Clerici, Mario; Roilides, Emmanuel; Butler, Karina M.; DePalma, Louis; Venzon, David; Shearer, Gene M.; Pizzo, Philip A.

In: Blood, Vol. 80, No. 9, 01.11.1992, p. 2196-2202.

Research output: Contribution to journalArticle

Clerici, M, Roilides, E, Butler, KM, DePalma, L, Venzon, D, Shearer, GM & Pizzo, PA 1992, 'Changes in T-helper cell function in human immunodeficiency virus-infected children during didanosine therapy as a measure of antiretroviral activity', Blood, vol. 80, no. 9, pp. 2196-2202.
Clerici, Mario ; Roilides, Emmanuel ; Butler, Karina M. ; DePalma, Louis ; Venzon, David ; Shearer, Gene M. ; Pizzo, Philip A. / Changes in T-helper cell function in human immunodeficiency virus-infected children during didanosine therapy as a measure of antiretroviral activity. In: Blood. 1992 ; Vol. 80, No. 9. pp. 2196-2202.
@article{12628a39002645318f9a7a19a4233dac,
title = "Changes in T-helper cell function in human immunodeficiency virus-infected children during didanosine therapy as a measure of antiretroviral activity",
abstract = "Didanosine has shown activity against the human immunodeficiency virus (HIV) in both children and adults. We prospectively assessed T-helper cell (Th) function as determined by in vitro interleukin-2 (IL-2) production in response to a panel of T-cell stimuli in 22 HIV-infected children before and during didanosine therapy and we correlated the incidence of opportunistic and recurrent bacterial infections with changes in p24 antigen and CD4 counts. Didanosine (270, 360, or 540 mg/m2/d) was administered orally for periods ranging from 8 to 40 weeks (mean, 24 weeks). Five of six asymptomatic patients (Centers for Disease Control P-1) compared with 6 of 16 symptomatic (P-2) patients exhibited improved Th function (greater than threefold increase in IL-2 production to at least 2 of the 4 stimuli) during therapy. Of 12 patients without infections during therapy, 9 (75{\%}) showed improvement in Th function, compared with only 2 of 10 patients with infections (P = .03). Notably, the incidence of infections was not correlated with improvements in CD4 count or decreases in p24 antigen. Improvement in Th function during didanosine therapy is correlated with decreased incidence of infections. Assessment of Th function may provide an additional measurement of immunologic response to antiretroviral therapy. This is a US government work. There are no restrictions on its use.",
author = "Mario Clerici and Emmanuel Roilides and Butler, {Karina M.} and Louis DePalma and David Venzon and Shearer, {Gene M.} and Pizzo, {Philip A.}",
year = "1992",
month = "11",
day = "1",
language = "English",
volume = "80",
pages = "2196--2202",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Changes in T-helper cell function in human immunodeficiency virus-infected children during didanosine therapy as a measure of antiretroviral activity

AU - Clerici, Mario

AU - Roilides, Emmanuel

AU - Butler, Karina M.

AU - DePalma, Louis

AU - Venzon, David

AU - Shearer, Gene M.

AU - Pizzo, Philip A.

PY - 1992/11/1

Y1 - 1992/11/1

N2 - Didanosine has shown activity against the human immunodeficiency virus (HIV) in both children and adults. We prospectively assessed T-helper cell (Th) function as determined by in vitro interleukin-2 (IL-2) production in response to a panel of T-cell stimuli in 22 HIV-infected children before and during didanosine therapy and we correlated the incidence of opportunistic and recurrent bacterial infections with changes in p24 antigen and CD4 counts. Didanosine (270, 360, or 540 mg/m2/d) was administered orally for periods ranging from 8 to 40 weeks (mean, 24 weeks). Five of six asymptomatic patients (Centers for Disease Control P-1) compared with 6 of 16 symptomatic (P-2) patients exhibited improved Th function (greater than threefold increase in IL-2 production to at least 2 of the 4 stimuli) during therapy. Of 12 patients without infections during therapy, 9 (75%) showed improvement in Th function, compared with only 2 of 10 patients with infections (P = .03). Notably, the incidence of infections was not correlated with improvements in CD4 count or decreases in p24 antigen. Improvement in Th function during didanosine therapy is correlated with decreased incidence of infections. Assessment of Th function may provide an additional measurement of immunologic response to antiretroviral therapy. This is a US government work. There are no restrictions on its use.

AB - Didanosine has shown activity against the human immunodeficiency virus (HIV) in both children and adults. We prospectively assessed T-helper cell (Th) function as determined by in vitro interleukin-2 (IL-2) production in response to a panel of T-cell stimuli in 22 HIV-infected children before and during didanosine therapy and we correlated the incidence of opportunistic and recurrent bacterial infections with changes in p24 antigen and CD4 counts. Didanosine (270, 360, or 540 mg/m2/d) was administered orally for periods ranging from 8 to 40 weeks (mean, 24 weeks). Five of six asymptomatic patients (Centers for Disease Control P-1) compared with 6 of 16 symptomatic (P-2) patients exhibited improved Th function (greater than threefold increase in IL-2 production to at least 2 of the 4 stimuli) during therapy. Of 12 patients without infections during therapy, 9 (75%) showed improvement in Th function, compared with only 2 of 10 patients with infections (P = .03). Notably, the incidence of infections was not correlated with improvements in CD4 count or decreases in p24 antigen. Improvement in Th function during didanosine therapy is correlated with decreased incidence of infections. Assessment of Th function may provide an additional measurement of immunologic response to antiretroviral therapy. This is a US government work. There are no restrictions on its use.

UR - http://www.scopus.com/inward/record.url?scp=0026788364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026788364&partnerID=8YFLogxK

M3 - Article

C2 - 1421391

AN - SCOPUS:0026788364

VL - 80

SP - 2196

EP - 2202

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -